- Investing.com
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials; and PORT-7, a potent and selective antagonist of the adenosine A2B receptor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Metrics to compare | PRTG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPRTGPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.6x | −2.9x | −0.5x | |
PEG Ratio | −0.03 | 0.02 | 0.00 | |
Price/Book | −145.4x | 2.2x | 2.6x | |
Price / LTM Sales | - | 8.6x | 3.3x | |
Upside (Analyst Target) | - | 199.2% | 38.7% | |
Fair Value Upside | Unlock | 8.1% | 5.0% | Unlock |